Prasugrel-related hepatotoxicity
Prasugrel is usually preferred over Clopidogrel to reduce the risk of recurrent coronary thrombosis in patients who undergo percutaneous coronary interventions during an acute coronary syndrome owing to its more potent and more rapid antithrombotic activation. Little is known about Prasugrel-induce...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Pakistan Medical Association
2022-10-01
|
| Series: | Journal of the Pakistan Medical Association |
| Online Access: | https://www.ojs.jpma.org.pk/index.php/public_html/article/view/3179 |
| _version_ | 1797820852523237376 |
|---|---|
| author | Zeki Dogan Mustafa Yurtdas Gokhan Bektasoglu |
| author_facet | Zeki Dogan Mustafa Yurtdas Gokhan Bektasoglu |
| author_sort | Zeki Dogan |
| collection | DOAJ |
| description |
Prasugrel is usually preferred over Clopidogrel to reduce the risk of recurrent coronary thrombosis in patients who undergo percutaneous coronary interventions during an acute coronary syndrome owing to its more potent and more rapid antithrombotic activation. Little is known about Prasugrel-induced hepatotoxicity, although mild-to-moderate alanine transaminase (ALT) and gamma glutamyl transpeptidase (GGT) elevations have been noticed in post-marketing surveillance. Herein, we report the case of a patient with Prasugrel-related hepatotoxicity that was reverted after switching from Prasugrel to Ticagrelor.
Keywords: Percutanous coronary interventions, antiplatelet drug, Prasugrel, hepatotoxicity.
|
| first_indexed | 2024-03-13T09:44:23Z |
| format | Article |
| id | doaj.art-51f3c7bb02d7467eac0f2e8f7f417337 |
| institution | Directory Open Access Journal |
| issn | 0030-9982 |
| language | English |
| last_indexed | 2024-03-13T09:44:23Z |
| publishDate | 2022-10-01 |
| publisher | Pakistan Medical Association |
| record_format | Article |
| series | Journal of the Pakistan Medical Association |
| spelling | doaj.art-51f3c7bb02d7467eac0f2e8f7f4173372023-05-25T04:21:38ZengPakistan Medical AssociationJournal of the Pakistan Medical Association0030-99822022-10-01721110.47391/JPMA.3179Prasugrel-related hepatotoxicityZeki Dogan0Mustafa Yurtdas1Gokhan Bektasoglu2Department of Cardiology, Istanbul Atlas University, School of Medicine, Medicine Hospital, TurkeyDepartment of Cardiology, Istanbul Atlas University, School of Medicine, Medicine Hospital, TurkeyDepartment of Cardiology, Istanbul Atlas University, School of Medicine, Medicine Hospital, Turkey Prasugrel is usually preferred over Clopidogrel to reduce the risk of recurrent coronary thrombosis in patients who undergo percutaneous coronary interventions during an acute coronary syndrome owing to its more potent and more rapid antithrombotic activation. Little is known about Prasugrel-induced hepatotoxicity, although mild-to-moderate alanine transaminase (ALT) and gamma glutamyl transpeptidase (GGT) elevations have been noticed in post-marketing surveillance. Herein, we report the case of a patient with Prasugrel-related hepatotoxicity that was reverted after switching from Prasugrel to Ticagrelor. Keywords: Percutanous coronary interventions, antiplatelet drug, Prasugrel, hepatotoxicity. https://www.ojs.jpma.org.pk/index.php/public_html/article/view/3179 |
| spellingShingle | Zeki Dogan Mustafa Yurtdas Gokhan Bektasoglu Prasugrel-related hepatotoxicity Journal of the Pakistan Medical Association |
| title | Prasugrel-related hepatotoxicity |
| title_full | Prasugrel-related hepatotoxicity |
| title_fullStr | Prasugrel-related hepatotoxicity |
| title_full_unstemmed | Prasugrel-related hepatotoxicity |
| title_short | Prasugrel-related hepatotoxicity |
| title_sort | prasugrel related hepatotoxicity |
| url | https://www.ojs.jpma.org.pk/index.php/public_html/article/view/3179 |
| work_keys_str_mv | AT zekidogan prasugrelrelatedhepatotoxicity AT mustafayurtdas prasugrelrelatedhepatotoxicity AT gokhanbektasoglu prasugrelrelatedhepatotoxicity |